Walvax沃森生物

CN
EN

Products List

Walvax has successfully developed 8 licensed vaccines, including 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) and Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (HPV2).

 

Walvax proactively promotes PQ application of its products, and is proceeding with PQ application of multiple products. In 3 to 5 years, Walvax's WHO-PQ will yield fruitful results, which brings its internationalization to a higher level.

Quick Links

Pipeline
Group ACYW135 Meningococcal Polysaccharide Vaccine

Prevention of invasive meningococcal diseases caused by Neisseria meningitidis serogroups A, C, Y and W135 for use in individuals aged ≥ 2 years.

Group A and C Meningococcal Polysaccharide Vaccine

Prevention of epidemic cerebrospinal meningitis caused by Neisseria meningitidis serogroups A and C for use in individuals aged ≥ 2 years.

Group A and Group C Meningococcal Conjugate Vaccine

Prevention of invasive meningococcal diseases caused by Neisseria meningitidis serogroups A and C for use in infants and children 3 months through 5 years of age.